Disc Medicine, Inc. Overview
Pro stress-test →Disc Medicine assembles a portfolio of clinical and preclinical product candidates targeting fundamental biological pathways associated with red blood cell formation and function, primarily heme biosynthesis and iron homeostasis. Founded in 2017 and headquartered in Watertown, Massachusetts, the company pursues novel treatments for serious hematologic diseases with potential first-in-class candidates.
Strategic Profile
Pro stress-test →The pipeline includes bitopertin for erythropoietic porphyrias and diamond-blackfan anemia; DISC-0974 for anemia of myelofibrosis and chronic kidney disease; and DISC-3405 for polycythemia vera and other hematologic disorders. Disc ended 2025 with approximately $791 million in cash and marketable securities and expects runway into 2029, providing substantial capital for development while the company navigates recent regulatory setbacks.
Competitive Landscape
Pro stress-test →Disc competes in the specialized hematology sector targeting rare blood disorders through novel mechanism-based therapeutics. Competitors include traditional erythropoiesis-stimulating agents and other development-stage biotech companies targeting similar pathways, though Disc's focus on heme biosynthesis and iron homeostasis represents a differentiated approach with limited direct competition in specific indications.
Industry Context
Disc Medicine, Inc. operates in Clinical-Stage Biopharmaceuticals / Hematology.
Key facts
Founded: 2017 · Headquarters: Watertown, US · Revenue: Negative (pre-revenue clinical stage) · Market cap: $2.51B